- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.52 Å
- Oligo State
- homo-dimer
- Ligands
- 8 x ZN: ZINC ION(Non-covalent)
- 2 x SFG: SINEFUNGIN(Non-covalent)
SFG.5: 16 residues within 4Å:- Chain A: M.138, G.139, W.140, S.174, Y.175, R.199, F.200, I.201, N.202, H.203, Y.244, W.249, F.256, T.257, C.258, Q.259
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:Y.244
- Hydrogen bonds: A:W.140, A:S.174, A:Y.175, A:R.199, A:N.202, A:N.202, A:H.203, A:H.203, A:Y.244, A:Q.259
- Water bridges: A:R.134, A:S.174, A:Y.175, A:I.201
SFG.11: 16 residues within 4Å:- Chain B: M.138, G.139, W.140, S.174, Y.175, R.199, F.200, I.201, N.202, H.203, Y.244, W.249, F.256, T.257, C.258, Q.259
13 PLIP interactions:13 interactions with chain B- Hydrophobic interactions: B:Y.244
- Hydrogen bonds: B:W.140, B:S.174, B:Y.175, B:Y.175, B:R.199, B:N.202, B:N.202, B:H.203, B:H.203, B:Q.259
- Water bridges: B:S.174, B:I.201
- 2 x 01: 3,6,6-trimethyl-~{N}-[(2~{S})-1-[[4-(1-methylpiperidin-4-yl)oxyphenyl]amino]-1-oxidanylidene-hexan-2-yl]-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide
01.6: 16 residues within 4Å:- Chain A: A.167, D.168, D.173, S.174, L.176, F.177, D.178, D.180, P.211, R.213, F.242, D.243, Y.244, R.247, F.248, I.251
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:D.173, A:L.176, A:F.177, A:D.180, A:F.242, A:Y.244, A:F.248, A:I.251
- Hydrogen bonds: A:L.176, A:D.178, A:Y.244, A:R.247
- Water bridges: A:F.248
- Salt bridges: A:D.173
- pi-Stacking: A:F.177
01.12: 17 residues within 4Å:- Chain B: Y.157, A.167, D.168, D.173, S.174, L.176, F.177, D.178, P.211, R.213, I.226, F.242, D.243, Y.244, R.247, F.248, I.251
18 PLIP interactions:18 interactions with chain B- Hydrophobic interactions: B:D.173, B:L.176, B:F.177, B:F.177, B:I.226, B:F.242, B:Y.244, B:Y.244, B:Y.244, B:F.248, B:I.251
- Hydrogen bonds: B:L.176, B:D.178, B:Y.244, B:F.248
- Water bridges: B:R.247
- Salt bridges: B:D.173
- pi-Stacking: B:F.177
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nishigaya, Y. et al., Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment. Bioorg.Med.Chem.Lett. (2024)
- Release Date
- 2025-01-22
- Peptides
- Histone-lysine N-methyltransferase EHMT2: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.52 Å
- Oligo State
- homo-dimer
- Ligands
- 8 x ZN: ZINC ION(Non-covalent)
- 2 x SFG: SINEFUNGIN(Non-covalent)
- 2 x 01: 3,6,6-trimethyl-~{N}-[(2~{S})-1-[[4-(1-methylpiperidin-4-yl)oxyphenyl]amino]-1-oxidanylidene-hexan-2-yl]-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nishigaya, Y. et al., Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment. Bioorg.Med.Chem.Lett. (2024)
- Release Date
- 2025-01-22
- Peptides
- Histone-lysine N-methyltransferase EHMT2: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B